NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial ...

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.

Sirolimus 1mg/mL; contains alcohol. Sirolimus inhibits T-lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation by a ...

Orchestra BioMed (Nasdaq:OBIO) announced that it received FDA investigational device exemption (IDE) for its Virtue ...

In participants of the CONVERT trial, which enrolled recipients of kidney transplants, conversion of immunosuppressive therapy from calcineurin inhibitors to sirolimus did not improve renal function.

emphasized the significance of Virtue SAB's novel mechanism of action. Unlike paclitaxel-based DCBs, it delivers a high liquid dose of sirolimus with anti-restenotic, anti-inflammatory ...